Alex Zhavoronkov

[Administrator]

Aleksandrs Zavoronkovs

Co-founder and CEO of Insilico Medicine, Inc.

facebook.com/biogerontology

x.com/biogerontology

linkedin.com/in/zhavoronkov

Alex Zhavoronkov on Wikipedia

Projects:

Book “The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy”, 2013

Book "Dating AI, A Guide to Falling In Love with Artificial Intelligence", 2012

Owner of .ai domain names

 

[Administrator]

2018 AI 100 Startup: Insilico

Published on Jan 17, 2018

Interview with Alex Zhavoronkov, CEO of Insilico, filmed at the A-ha conference December 12, 2017

 

[Administrator]

Drug Discovery, Biotech, and AI with Alex Zhavoronkov, CEO, Insilico Medicine (CXOTalk #327)

Published on Feb 11, 2019

Artificial intelligence offers the promise of better health, faster drug discovery and testing, to create improved medical outcomes for patients. We talk with a world expert on using AI in life sciences to discover and develop drugs faster and less expensively. AI and machine learning help select therapy candidates and assist with clinical trials.

Read the complete transcript

Dr. Alex Zhavoronkov is the founder and CEO of Insilico Medicine, a leader in the next-generation artificial intelligence for drug discovery, biomarker development, and aging research. Prior to Insilico, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI. Since 2012 he published over 130 peer-reviewed research papers and 2 books. For six years in a row, he has organized the annual Aging Research for Drug Discovery and Artificial Intelligence for Healthcare forums at Basel Life/EMBO in Basel. Alex is an adjunct professor at the Buck Institute for Research on Aging.

 

[Administrator]

Article "Insilico CEO Alex Zhavoronkov Shares His Vision for ‘Pharma Superintelligence’"
From IPF trials to Parkinson’s therapies, Insilico Medicine CEO Alex Zhavoronkov shares how A.I. is reshaping drug discovery.

September 18, 2025